rel="nofollow" href="#ulink_e6b3c528-8151-50fd-9fc0-f902d8b1e2b9">430]. Fibrates (and analogues) should be favored if triglycerides are increased. These drugs also lower plasma fibrinogen and are beneficial for hypercoagulation and impaired microcirculation. However, the combination of statins and fibrates (and analogues) should definitely be avoided, because it increases the risk of myositis and other severe adverse drug effects.
Prophylactic treatment of hypercoagulation with aspirin or other drugs that reduce platelet aggregation has been recommended [228,304].
Treatment of the metabolic syndrome requires lifestyle changes. Physical activity should be integrated into everyday life, and every smoker should be offered a course in giving up smoking.
This kind of broad approach has been proven to be effective both in preventing [337,338] and in managing [431] type 2diabetes mellitus. The task for the future will be to integrate this experience into public health.
References
[1] National Diabetes Data Group. Classification and diagnosis of diabetes mellitus and other categories of glucose intolerance. Diabetes 1979; 28: 1039-57.
[2] World Health Organization. Diabetes mellitus: Report of a WHO Study Group. Geneva: World Health Organization; 1985.
[3] American Diabetes Association. Report of the Expert Committee on Diagnosis and Classification of Diabetes Mellitus. Diabetes Care 1998; 21 (suppl 1): S5-19.
[4] The DECODE Study Group on behalf of the European Diabetes Epidemiology Group. Consequences of the new criteria for diabetes in older men and women-the DECODE study (Diabetes epidemiology: Collaborative analysis of diagnostic criteria in Europe). Diabetes Care 1999; 22: 1667-71.
[5] The DECODE Study Group on behalf of the European Diabetes Epidemiology Group. Glucose tolerance and cardiovascular mortality: comparison of fasting and 2-hour diagnostic criteria. Arch Intern Med 2001; 161: 397-404.
[6] Rathmann W, Giani G, Mielck A. Cardiovascular risk factors in newly diagnosed abnormal glucose tolerance: comparison of 1997 ADA and 1985 WHO criteria. Diabetologia 1999; 42: 1268-9.
[7] Tominaga M, Eguchi H, Manaka H, Igarashi K, Kato T, Sekikawa A. Impaired glucose tolerance is a risk factor for cardiovascular disease, but not impaired fasting glucose. Diabetes Care 1999; 22: 920-4.
[8] Balkau B. The Decode study: Diabetes epidemiology: collaborative analysis of diagnostic criteria in Europe. Diabetes Metab (Paris) 2000; 26: 282-6.
[9] Ekoe JM. Epidemiology and etiopathogenesis of IDDM in other ethnic groups. In: Alberti KGMM. DeFronzo RA, Keen H, Zimmet P, editors. International textbook of diabetes mellitus. Chichester: John Wiley and Sons Ltd: 1992:129-45.
[10] Green A, Gale EAM, Patterson CC, for the EURODIAB ACE Study Group. Incidence of childhood-onset insulin-dependent diabetes mellitus: The EURODIAB ACE Study. Lancet 1992; 339: 905-9.
[11] Karvonen M, Tuomilehto J, Libman I, La Porte R, for the World Health Organization DIAMOND Project Group. A review of the recent epidemiological data on the worldwide incidence of type 1 (insulin-dependent) diabetes mellitus. Diabetologia 1993; 36: 883-92.
[12] Schiel R, Mueller UA. GAD autoantibodies in a selection-free population of insulin treated diabetic patients: indicator of a high prevalence of LADA? Diab Res Clin Pract 2000; 49: 33-40.
[13] Neu A, Kehrer M, Hub R, Ranke MB. Incidence of diabetes in German children aged 0-14 years. Diabetes Care 1997; 20: 530-3.
[14] Onkamo P, Väänänen S, Karvonen M, Tuomilehto J. Worldwide increase in incidence of type 1 diabetes–the analysis of the data on published incidence trends. Diabetologia 1999; 42: 1395-403.
[15] Rosenbauer J, Herzig P, Kries R von, Neu A, Giani G. Temporal, seasonal and geographical incidence patterns of type 1 diabetes mellitus in children under 5 years of age In Germany. Diabetologia 1999; 42: 1055-9.
[16] Karvonen M, Pitkäniemi J, Tuomilehto J, the Finnish Childhood Diabetes Registry Group. The onset age of type 1 diabetes in Finnish children has become younger. Diab Care 1999; 22: 1066-70.
[17] Bingley PJ, Douek JF, Rogers CA, Gale EAM, on behalf of the BOX (Bart's-Oxford) Study Group. Influence of maternal age at delivery and birth order on the risk of type 1 diabetes in childhood: prospective population based family study. BMJ 2000; 321:420-4.
[18] Deckert T, Poulsen JE, Larsen M. Prognosis of diabetics with diabetes onset before the age of thirty one, I: Survival, causes of death, and complications. Diabetologia 1978; 14: 363-70.
[19] Rossing P, Hougaard P, Borch-Johnsen K, Parving HH. Predictors of mortality in insulin dependent diabetes: 10 year observational follow-up study. BMJ 1996; 313: 779-84.
[20] Borch-Johnsen K, Kreiner S, Deckert T. Mortality of type 1 (insulin-dependent) diabetes mellitus in Denmark: a study of relative mortality in 2930 Danish type 1 diabetic patients diagnosed from 1933-1972. Diabetologia 1986; 29:767-72.
[21] American Diabetes Association. Diabetes 1996 vital statistics. Alexandria, Va: American Diabetes Association, 1996.
[22] Diabetes Epidemiology Research International (DERI) Mortality Study Group: International evaluation of cause-specific mortality and IDDM. Diabetes Care 1990; 14: 55-60.
[23] Portuese E, Orchard T. Mortality in insulin-dependent diabetes mellitus. In: Harris MI, Cowie CC, Stern MP, Boyko EJ, Reiber GE, Bennett PH, editors. Diabetes in America, 2nd ed, Bethesda. Md: National Institutes of Diabetes and Digestive and Kidney Diseases; 1995: 221-32. NIH publication no. 95-1468.
[24] Stephenson JM, Kenny S, Stevens LK, Fuller JH, Lee E, and the WHO Multinational Study Group. Proteinuria and mortality in diabetes: the WHO multinational study of vascular disease in diabetes. Diabet Med 1995; 12: 149-55.
[25] Centers for Disease Control. Diabetes surveillance 1993. Atlanta, Ga: US Department of Health and Human Services, Public Health Service, Centers for Disease Control; 1993.
[26] Tattersall RB, Gale EAM, Mortality. In: Frier BM, Fisher BM, editors. Hypoglycaemia and diabetes: clinical and physiological aspects. London: Edward Arnold, 1993.
[27] Zimmet P, Dowse G, Finch C, Serjeantson S, King H. The epidemiology and natural history of NIDDM: lessons from the South Pacific. Diabet Metab Rev 1990; 6: 91-124.
[28] Bennet PH, Bogardus C, Tuomilehto J, Zimmet P. Epidemiology and natural history of NIDDM: non-obese and obese. In: Alberti KGMM, DeFronzo RA, Keen H, Zimmet P, editors. International textbook of diabetes mellitus. Chichester: John Wiley and Sons Ltd; 1992: 147-76.
[29] Panzram G. Mortality and survival in type 2 (non-insulin-dependent) diabetes mellitus. Diabetologia 1987; 30: 123-31.
[30] Groeneveld Y, Petri H, Hermanst J, Springer MD. Relationship between blood glucose level and mortality in type 2 diabetes mellitus: a systematic review. Diabet Med 1999; 16: 2-13.
[31] Bain SC, Mijovic CH, Barnett AH. Genetic factors in the pathogenesis of insulin-dependent diabetes mellitus. In: Pickup J, Williams G, editors. Textbook of diabetes. Oxford: Blackwell Science: 1997: 13.1-13.13.
[32] Atkinson MA, Leiter EH. The NOD mouse model of type 1 diabetes: as good as it gets? Nat Med 1999; 5: 601-4.
[33] Levy-Marchal C, Patterson C, Green A. on behalf of the
